Ddu Attended CPhI North America Great Success with the “Internet + Cross-border medical trade” Marketing Model

May 3, 2018  Source: Ddu 2,341

CPhI North America was held in Philadelphia, USA from April 24th to April 26th, 2018. Ddu, the leading global pharmaceutical & medical device B2B online platform, attended the exhibition and showcased their new marking model in the United State, but received great feedback from across the globe.

CPhI North America is the only professional pharmaceutical and chemical exhibition in the United States. It enjoys a good reputation in the international chemical industry and specializes in customized synthesis business.

It is reported that this year’s exhibition brought together more than 630 pharmaceutical exhibitors and more than 7,400 professional visitors, creating a broader platform for manufacturers and traders in the pharmaceutical industry.

During the exhibition, visitors flooded to Ddu’s booth, showing great interest in the “Internet + cross-border medical trade” marketing model, commenting that the platform is user-friendly and accessible.

Ing. Deborah de Motta, director of Wellco Pharmaceutical Co., Ltd, stated that she believes Ddu will be an important platform for them to look for raw materials, APIs and packing materials amongst numerous other products.

Ddu attached great importance in the communication with every one engaged in the medical trade, continuously obtaining the latest market demands and actively boosting business deals. So far, Ddu has participated in 7 well-known exhibitions in China, Dubai, South Korea, India, Turkey, the United States, and Singapore in 2018.

Ddu, with its “Internet + cross-border medical trade” marketing model, is dedicated to bringing more quality products and services to more countries and regions in order to achieve win-win cooperation in the near future.

By Ddu
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.